Hemab Therapeutics (NASDAQ:COAG) Chief Executive Officer Benny Sorensen outlined the company’s development plans following its recent initial public offering during a fireside chat with Jefferies biotech analyst Maury Raycroft.
Sorensen said Hemab is pursuing a strategy to build “a multiple product, exclusive coagulation franchise company” focused on blood coagulation disorders. The company’s lead program, sutacimig, has completed a Phase I/II study in Glanzmann’s thrombasthenia and is expected to enter a pivotal Phase III trial in the second half of this year, he said.